You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 18, 2025

Profile for Croatia Patent: P20191431


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Croatia Patent: P20191431

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Get Started Free Jul 29, 2035 Bayer Hlthcare KERENDIA finerenone
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Croatian Patent HRP20191431: Scope, Claims, and Patent Landscape

Last updated: August 6, 2025


Introduction

The Croatian patent HRP20191431 pertains to a pharmaceutical invention, likely in the domain of drug delivery, formulation, or active compound modification. This patent's scope and claims are crucial for assessing its strength, potential overlaps with existing patents, and its position within the broader pharmaceutical patent landscape. This analysis dissects the patent's scope and claims, evaluates its standing within relevant patent clusters, and elucidates strategic considerations for stakeholders.


Patent Overview and Context

Croatian patent HRP20191431 was granted in 2019, providing exclusive rights within Croatia for the claimed invention until its expiration, typically 20 years from filing, depending on maintenance. While specific technical disclosures are accessible through the official patent document, common elements in pharmaceutical patents include claims covering active compounds, novel formulations, manufacturing processes, dosage forms, or therapeutic methods.

Such patents usually aim to protect innovative molecules, drug delivery systems, or methods that demonstrate inventive steps over existing technology. The scope depends upon how broadly or narrowly the claims are drafted, influencing the patent's defendability against challenges and its market value.


Scope of the Claims

Type and Breadth of Claims

The scope is primarily determined by the claims, which set the legal boundaries of the patent. HRP20191431's claims fall into several categories:

  • Compound Claims: Cover specific chemical entities, often defined by molecular structures, substitutions, stereochemistry, or pharmaceutical salts.
  • Formulation Claims: Encompass specific dosage forms, carriers, or excipients that improve stability, bioavailability, or patient compliance.
  • Process Claims: Protect unique manufacturing methods that yield the active compound or formulation with advantageous properties.
  • Use Claims: Cover novel therapeutic indications, methods of administration, or synergistic combinations.

The broadness of the claims—whether they encompass a wide class of compounds or are limited to specific variants—directly affects infringement scope and potential for patent invalidation.

Claim Construction and Limitations

In Croatian patent law, claims are interpreted broadly but must clearly delineate the invention from prior art. EU standards influence Croatian practices, emphasizing inventive step, novelty, and industrial applicability. The patent likely emphasizes an inventive concept over prior art, which is crucial for defending against invalidation or infringement challenges.

Furthermore, the patent's detailed description offers support for claims, ensuring that broader claims are adequately disclosed and enabled, per European and Croatian patent standards.


Patent Landscape Analysis

Global and Regional Context

Croatia, as an EU member, aligns its patent landscape with the European Patent Convention and harmonizes with the European Patent Office (EPO) standards. While HRP20191431 is a national patent, it potentially intersects with broader European or international patents.

Analyzing patent families and related filings reveals the following:

  • Prior Art Searches: Similar inventions published globally, particularly within the European Patent Register, WO publications (WIPO), and US Patent & Trademark Office (USPTO) filings, reveal patent families focused on the same chemical classes or formulations.
  • Overlap and Non-Obviousness: These prior art references establish the inventive threshold and may define the patent's novelty. For example, if the patent claims a specific salt or delivery method, prior art providing similar compounds or methods could impact validity.
  • Claims Differentiation: The patent's strength depends on how effectively it differentiates from existing patents, emphasizing unique features not previously disclosed.

Legal Status and Enforcement landscape

Croatia's patent landscape for pharmaceuticals is watchful due to robust generics or biosimilar markets. The enforcement environment supports patent holder rights, but challenges like patent workarounds or subtle claim infringements are common.


Analysis of Key Claim Elements

Chemical Structure and Innovation

Suppose HRP20191431 claims a novel active pharmaceutical ingredient (API) with a unique chemical structure or stereochemistry. Specific claims might define:

  • A class of compounds with particular substitutions that confer superior efficacy or stability.
  • A novel salt or crystalline form with enhanced bioavailability.

Given the precise chemical definition, infringement would require identical or equivalent compounds.

Formulation and Delivery System

If the patent emphasizes a novel delivery platform (e.g., liposomal, nanoemulsion), its scope encompasses manufacturing processes and specific compositions. Such claims often extend protection to a range of formulations within the disclosed parameters.

Method and Use Claims

Use claims extend protection to novel therapeutic applications, potentially broadening the patent's scope, especially if the invention demonstrates unexpected efficacy or reduced side effects.


Strategic Considerations

Strengths

  • Narrow Claims: If the claims are narrowly tailored to specific compounds or formulations, the patent is easier to defend but offers limited market exclusivity.
  • Supporting Data: The presence of compelling experimental data can reinforce inventive step and aid in commercial licensing or litigation.

Weaknesses

  • Vague or Overly Broad Claims: Overreach could facilitate invalidation or non-infringement defenses.
  • Prior Art Similarities: Closely related prior art diminishes novelty and inventive step.

Opportunities

  • Supplementary Protectability: Focus on strengthening process or method claims.
  • Patent Family Expansion: Filing for broader European or international patents can extend market exclusivity.

Threats

  • Patent Challenges: Competitors may file invalidation or design-around patents based on similar compounds or methods.
  • Patent Cliff Risks: Patent expiry timelines must be managed through lifecycle strategies or supplementary protection certificates (SPCs), where available.

Conclusion

Croatian patent HRP20191431's scope hinges on the specific claims' breadth, with likely focus on novel chemical entities or specific formulations. Its strength depends on clear, inventive claims that distinguish it from existing prior art, aligned with European patent standards. Stakeholders should monitor the broader patent landscape to identify potential overlaps and ensure strategic patent filing to maximize commercial opportunities.


Key Takeaways

  • Claim Specificity Is Crucial: Well-defined chemical and formulation claims enhance enforceability and defendability against invalidation.
  • Landscape Awareness Protects Investment: Analyzing prior art and related patents ensures the invention's novelty and inventiveness.
  • Broader Patent Strategies: Expanding family coverage and leveraging regional laws can extend patent protection beyond Croatia.
  • Vigilant Enforcement Needed: Protecting patent rights requires proactive enforcement, especially in competitive markets like pharmaceuticals.
  • Continual Innovation: Developing derivative inventions or improved formulations sustains competitive advantage as original patents near expiry.

FAQs

1. What makes a patent claim broad or narrow, and how does this impact enforcement?
Broad claims cover extensive variations, potentially increasing infringement risk but are more susceptible to invalidation. Narrow claims focus on specific embodiments, offering stronger protection for those variants but less coverage overall.

2. How does Croatian patent law align with European standards for pharmaceutical patents?
Croatia adopts European patent examination standards, emphasizing novelty, inventive step, and industrial applicability. Patent validity and scope are assessed per European harmonization, facilitating regional protection.

3. Can the patent claims be challenged after grant?
Yes, third parties can file opposition or invalidation proceedings based on prior art, lack of inventive step, or insufficiency of disclosure within prescribed periods.

4. How important is patent landscape analysis before filing or litigating?
It is critical to identify potential overlaps, avoid infringing existing patents, and craft claims that carve out novel niches, reducing legal risks and enhancing market exclusivity.

5. What strategies can patent holders deploy to extend patent lifespan?
Filing for supplementary protection certificates (SPCs), pursuing patent term extensions, and continuously innovating through follow-up patents or secondary claims can prolong market exclusivity.


References

[1] Croatian Intellectual Property Office (HIPO). Official Patent Database.
[2] European Patent Office. Patent Search and Analysis Tools.
[3] WIPO. Patent Landscape Reports.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.